Financial Results for the Year Ended March 31, 2015 <Supplement>

As of May 8, 2015

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma

Table of Contents

1 Summary of Financial Results for FY2014 Ended March 31, 2015 and Forecasts for FY2015

(Amounts less than ¥100 million are rounded.)

1. Summary of Financial Results for FY2014

[Billion yen]

Net Sales	415.1	Y-on-Y	2.4	0.6 %
Domestic sales	337.2	Y-on-Y	(16.1)	(4.6 %)
Overseas sales	77.9	Y-on-Y	18.6	31.3 %

Net sales increased 0.6%, or ¥2.4 billion, to ¥415.1 billion.
In the domestic sales of ethical drugs, favorable sales growth was recorded by Remicade, an anti-TNFα monoclonal antibody and TENELIA, for the treatment of type2 diabetes mellitus. However, there were the growing impact of generics and NHI price revision in April 2014. As a result, the domestic sales of ethical drugs decreased 5.2%, year-on-year, to ¥323.9 billion.
Overseas sales of ethical drugs were ¥23.0 billion, up 4.6%, year-on-year, due to depreciation of the yen.
Royalty income, etc. increased 60.7%, year-on-year, to ¥60.4 billion due to the increase in royalty revenue from Gilenya, for the treatment of multiple sclerosis, licensed to Novartis and from INVOKANA and the fixed dose combination with metformin (IR), for the treatment of type2 diabetes mellitus, licensed to Janssen Pharmaceuticals.

Operating Income	67.1	Y-on-Y	8.0	13.6 %

Operating income was ¥67.1 billion, up 13.6%, or ¥8.0 billion, year-on-year.
Despite the influence of NHI drug price revision, gross profit increased ¥2.2 billion, year-on-year, to ¥245.5 billion due to the increase in royalty revenue. As a result, the cost of sales ratio improved by 0.1 percentage points, year-on-year, to 40.9%.
SG&A expenses decreased ¥5.8 billion, year-on-year, to ¥178.4 billion due to the decrease in the labor cost accompanying the decrease in retirement benefit expenses and R&D expenses related to the progress of development phase.

[Billion yen]

Ordinary Income	67.7	Y-on-Y	5.8	9.3 %

Net Income	39.5	Y-on-Y	(5.9)	(13.0 %)

Ordinary income was up 9.3%, or ¥5.8 billion, year-on-year, to ¥67.7 billion, and net income was down 13.0%, or ¥5.9 billion, year-on-year, to ¥39.5 billion.
Foreign exchange gain decreased to ¥0.4 billion (foreign exchange gain was ¥2.5 billion in the previous fiscal year). As a result, non-operating income and loss worsened by ¥2.2 billion, year-on-year.
Extraordinary income was ¥13.7 billion, mainly because the Company recorded gain on sales of property, plant and equipment, such as sales of former Nihonbashi Building. In the previous fiscal year, the Company recorded extraordinary income of ¥15.3 billion, such as profit on arbitration award.
Extraordinary loss was ¥18.6 billion, including restructuring expenses, such as sales of Kashima Plant and the closing of Kazusa office, related to one of the strategic challenges of Medium-Term Management Plan; "accelerating operational and structural reforms." In the previous fiscal year, the Company recorded extraordinary loss of ¥4.8 billion, such as special retirement expenses.

2. Summary of Forecasts for FY2014

[Billion yen]

Net Sales	396.0	Y-on-Y	(19.1)	(4.6 %)
Operating Income	67.5	Y-on-Y	0.4	0.5 %
Ordinary Income	67.0	Y-on-Y	(0.7)	(1.0 %)
Net Income	40.5	Y-on-Y	1.0	2.5 %

3. Dividends

	FY2015 (Estimate)		FY2014	
	End of 1st Half	For the Year	End of 1st Half	For the Year
Dividends per Share (¥)	22	44	20	42
Dividends Payout Ratio	-	60.9%	-	59.6%
prior to amortization of goodwill	-	48.8%	-	47.6%

2 Consolidated Financial Indicators for FY2014

(Amounts less than ¥100 million are rounded.)

1. Profit and Loss

(1) Profit and Loss

[Billion yen]

	FY2014	Y-on-Y			Comparison to Previous Forecasts			Notes [Y-on-Y Comparison]
		FY2013	Increase (Decrease)	Change %	Forecast*	Increase (Decrease)	Change %	
Net sales	**415.1**	412.7	2.4	0.6	406.0	9.1	2.2	See "Sales of Main Products" on page 5. Overseas sales ratio FY2013: 14.4% FY2014: 18.8% Average exchange rate FY2013:1US$=¥100.49 FY2014: 1US$＝¥110.62
Domestic sales	**337.2**	353.3	(16.1)	(4.6)	335.7	1.5	0.4	
Overseas sales	**77.9**	59.4	18.6	31.3	70.3	7.6	10.9	
Cost of sales	**169.6**	169.4	0.2	0.1	164.0	5.6	3.4	
Sales cost ratio	**40.9%**	41.0%			40.4%			
Gross operation profit	**245.5**	243.3	2.2	0.9	242.0	3.5	1.5	
SG&A expenses	**178.4**	184.2	(5.8)	(3.2)	182.0	(3.6)	(2.0)	
% of net sales	**43.0%**	44.6%			44.8%			
Operating income	**67.1**	59.1	8.0	13.6	60.0	7.1	11.9	
Ordinary income	**67.7**	61.9	5.8	9.3	61.5	6.2	10.0	
Extraordinary income and loss	**(5.0)**	10.6	(15.5)	-	0.0	(5.0)	-	
Net income	**39.5**	45.4	(5.9)	(13.0)	40.5	(1.0)	(2.5)	

(2) Cost of Sales and Selling, General and Administrative Expenses

[Billion yen]

	FY2014	Y-on-Y			Comparison to Previous Forecasts			Notes [Y-on-Y Comparison]
		FY2013	Increase (Decrease)	Change %	Forecast*	Increase (Decrease)	Change %	
Cost of sales	**169.6**	169.4	0.2	0.1	164.0	5.6	3.4	
% of Net sales	**40.9%**	41.0%			40.4%			
SG&A expenses	**178.4**	184.2	(5.8)	(3.2)	182.0	(3.6)	(2.0)	
% of Net sales	**43.0%**	44.6%			44.8%			
R&D expenses	**69.6**	70.4	(0.8)	(1.1)	72.5	(2.9)	(4.0)	
% of Net sales	**16.8%**	17.1%			17.9%			
Except R&D expenses	**108.8**	113.8	(5.0)	(4.4)	109.5	(0.7)	(0.7)	
Labor cost	**46.8**	48.4	(1.6)	(3.3)	46.2	0.6	1.2	Decrease in retirement benefit expenses, etc.
Amortization of goodwill	**10.9**	10.6	0.3	2.6	10.8	0.1	1.1	
Others	**51.1**	54.8	(3.7)	(6.8)	52.5	(1.4)	(2.7)	
Total labor cost	**81.1**	85.0	(3.9)	(4.6)	80.0	1.1	1.3	

*: Published forecasts announced on October 29, 2014 in the financial results of Q2 FY2014

(3) Non-operating Income and Loss

[Billion yen]

	FY2014	FY2013	Increase (Decrease)	Notes
Non-operating income	**3.8**	6.9	(3.1)	
Interest income	**1.6**	1.5	0.1	
Dividend income	**0.8**	0.8	(0.1)	
Equity in earnings of affiliates	**0.0**	0.6	(0.6)	
Foreign exchang gain	**0.4**	2.5	(2.1)	
Rent income	**0.2**	0.3	(0.1)	
Others	**0.8**	1.0	(0.3)	
Non-operating expenses	**3.2**	4.1	(0.9)	
Interest expense	**0.2**	0.1	0.1	
Adjustment for salaries for employees on secondment	**0.1**	0.8	(0.7)	
Donations	**1.5**	0.7	0.9	
Others	**1.4**	2.6	(1.2)	

(4) Extraordinary Income and Loss

[Billion yen]

	FY2014	FY2013	Increase (Decrease)	Notes
Extraordinary income	**13.7**	15.3	(1.7)	
Gain on sales of property, plant and equipment	**12.0**	1.0	11.0	Gain on the sale of a vacant lot of the former Nihonbashi building
Gain on sales of investment in securities	**1.1**	2.4	(1.3)	
Gain on sales of shares of subsidiaries and affiliates	**0.6**	-	0.6	Gain on the sales of shares of API Corporation and CMIC CMO, Ashikaga
Profit on arbitration award	**-**	11.0	(11.0)	FY2013: Reimbursed as the overpayment caused by the arbitration award of Remicade, etc
Gain on step acquisitions	**-**	0.9	(0.9)	FY2013: Gain on market value of stock holdings accompanied with acquisition of Medicago's shares
Extraordinary Loss	**18.6**	4.8	13.9	
Restructuring expenses	**12.3**	-	12.3	Close of Kazusa office, transfer of Kashima plant (Ibraki), withdrawal of business of Mitsubishi Pharma (Guangzhou) and losses according to relocation of head office and Kashima office (Osaka)
Amortization of goodwill	**3.5**	-	3.5	One-time amortization of goodwill of Bipha
Impairment loss	**2.6**	1.4	1.2	FY2014: Toda dormitory, etc. FY2013: Former research center in Yoshitomi, etc.
Loss on valuation of investment in securities	**0.1**	0.6	(0.5)	
Loss on sale of investments in securities	**0.1**	0.0	0.1	
Special retirement expenses	**-**	2.6	(2.6)	FY2013: Premium retirement expenses accroding to transfer to Japan Blood Products Organization and CMIC CMO, Ashikaga, etc.
Other	**0.1**	0.2	(0.1)	

(5) Taxes

[Billion yen]

	FY2014	FY2013	Increase (Decrease)	Notes
Income before income taxes and minority interests	**62.7**	72.4	(9.8)	
Income taxes-current	**29.8**	22.4	7.4	
Income taxes-deferred	**(4.4)**	4.7	(9.1)	
Minority interests	**(2.2)**	0.0	(2.2)	
Net Income	**39.5**	45.4	(5.9)	

(6) Sales of Main Products

[Billion yen]

	FY2014	Y-on-Y			Comparison to Forecasts		
		FY2013	Increase (Decrease)	Change %	Forecasts *1	Increase (Decrease)	Change %
Ethical drugs	**410.7**	407.2	3.5	0.9	401.3	9.4	2.3
Ethical drugs domestic sales	**323.9**	341.7	(17.8)	(5.2)	322.5	1.4	0.4
Remicade	**70.6**	76.3	(5.7)	(7.5)	70.3	0.3	0.4
Talion	**16.0**	13.7	2.3	16.7	16.4	(0.4)	(2.4)
Ceredist	**15.7**	17.8	(2.1)	(11.9)	15.4	0.3	1.7
Maintate	**14.1**	15.5	(1.3)	(8.5)	14.5	(0.3)	(2.1)
Venoglobulin IH	**11.6**	11.1	0.5	4.5	11.5	0.2	1.3
Simponi	**10.5**	9.4	1.1	11.6	11.5	(1.1)	(9.4)
Kremezin	**10.5**	12.6	(2.0)	(16.1)	10.5	0.0	0.1
Urso	**10.0**	12.4	(2.4)	(19.5)	9.9	0.1	1.1
Anplag	**8.3**	11.2	(2.9)	(25.7)	8.4	(0.1)	(0.8)
Depas	**8.1**	9.8	(1.7)	(17.7)	8.1	0.0	(0.4)
Lexapro	**8.0**	6.5	1.5	23.4	8.0	0.0	(0.4)
Radicut	**7.4**	10.9	(3.6)	(32.5)	7.2	0.2	2.6
Tenelia	**6.2**	0.8	5.4	684.1	6.5	(0.2)	(3.7)
Herbesser	**5.5**	6.9	(1.3)	(19.5)	5.5	0.0	(0.2)
Tanatril	**4.6**	6.2	(1.5)	(25.1)	4.6	0.0	0.3
BIKEN products [vaccine]	**30.3**	28.4	1.9	6.5	28.2	2.1	7.3
Tetrabik	**7.5**	6.7	0.8	11.9	7.1	0.5	6.5
Influenza	**7.4**	7.2	0.2	2.3	7.6	(0.2)	(2.7)
Varicella vaccine	**7.2**	3.6	3.6	99.6	5.2	1.9	36.9
Tanabe Seiyaku Hanbai products *2	**13.6**	14.1	(0.5)	(3.2)	13.7	(0.1)	(0.7)
Ethical drugs overseas sales	**23.0**	22.0	1.0	4.6	22.0	1.1	4.9
Herbesser	**6.5**	5.8	0.7	12.1	6.0	0.5	7.7
Argatroban (Novastan)	**2.1**	2.7	(0.5)	(19.7)	2.2	(0.1)	(4.7)
Tanatril	**1.8**	1.8	0.0	1.2	2.1	(0.3)	(12.1)
Contracted manufacturing products *3	**3.4**	5.8	(2.5)	(42.2)	3.3	0.1	1.6
Royalty income, etc.	**60.4**	37.6	22.8	60.7	53.6	6.8	12.7
Royalty from Gilenya	**43.9**	32.2	11.8	36.7	Undisclosed	-	-
Royalty from INVOKANA	**9.8**	Undisclosed	-	-	Undisclosed	-	-
OTC products	**4.0**	4.5	(0.5)	(10.5)	4.3	(0.3)	(6.7)
Total pharmaceuticals	**415.1**	412.7	2.4	0.6	406.0	9.1	2.2

*1: Published forecasts announced on October 29, 2014 in the financial results of Q2 FY2014.

*2: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*3:Active pharmaceutical ingredients and others ordered by other companies.

2. Financial Statement

(1) Balance Sheet

[Billion Yen]

	End of FY2014	Composition %	End of FY2013	Increase (Decrease)	Notes
Total Aseets	**929.3**	**100.0**	886.5	42.8	
Current Assets	**603.6**	**65.0**	540.5	63.2	
Cash and deposits	**50.2**	**5.4**	27.2	23.0	See Page 7, (2) Cash Flows Statement
Marketable securities	**118.8**	**12.8**	106.5	12.3	Increase in negotiable deposit, etc.
Notes and accounts receivable*1	**130.3**	**14.0**	123.5	6.8	
[Months/Revolution]	**3.77**		3.59	0.18	
Inventories	**85.1**	**9.2**	93.7	(8.6)	
Deposits	**192.8**	**20.7**	172.1	20.6	
Deferred income taxes	**8.3**	**0.9**	8.2	0.2	
Other	**18.1**	**2.0**	9.3	8.8	
Fixed Assets	**325.7**	**35.0**	346.0	(20.3)	
Property, plant and equipment	**92.5**	**10.0**	98.3	(5.8)	Investment for plant and equipment, 15.7; Depreciation, (7.5); Disposal, sale, impairment and others, (9.4), etc.
Intangible fixed assets	**116.9**	**12.6**	133.1	(16.2)	Investment for information system, 1.6; Depreciation, (1.6); Amortization of goodwill of the merger, (10.0), Amortization of goodwill of Bipha, (3.8)etc.
Investment in securities	**76.3**	**8.2**	71.6	4.7	Increase of fair market value, decrease due to sales of shares of API Corporation, etc.
Deferred income taxes	**0.8**	**0.1**	0.7	0.1	
Net defined benefit asset	**15.7**	**1.7**	16.3	(0.6)	
Other	**23.4**	**2.5**	26.0	(2.6)	
Total Liabilities	**128.9**	**13.9**	108.6	20.2	
Current Liabilities	**105.4**	**11.3**	81.8	23.6	
Notes and accounts payable*2	**34.6**	**3.7**	34.0	0.6	
Short-term debt	**-**	**-**	1.2	(1.2)	
Current maturities of long-term debt	**0.1**	**0.0**	0.1	0.0	
Accounts payable, other	**25.4**	**2.7**	16.8	8.6	
Income taxes payable	**19.8**	**2.1**	10.2	9.6	
Reserve for employees' bonuses	**10.0**	**1.1**	10.2	(0.2)	
Other	**15.5**	**1.7**	9.4	6.2	
Long-term Liabilities	**23.5**	**2.5**	26.8	(3.3)	
Long-term debts	**0.9**	**0.1**	1.0	(0.1)	
Deferred income taxes	**9.8**	**1.1**	13.4	(3.6)	
Reserve for health management allowances for HIV compensation	**1.7**	**0.2**	1.6	0.1	
Reserve for health management allowances for SMON compensation	**2.7**	**0.3**	3.0	(0.2)	
Reserve for HCV litigation	**2.0**	**0.2**	2.6	(0.6)	
Net defined benefit liability	**2.5**	**0.3**	2.1	0.3	
Other	**3.9**	**0.4**	3.2	0.7	
Net Assets	**800.4**	**86.1**	777.8	22.6	
Shareholders' equity	**776.0**	**83.5**	767.3	8.7	
Common stock	**50.0**	**5.4**	50.0	-	
Capital surplus	**451.2**	**48.6**	451.2	-	
Retained earnings	**275.3**	**29.6**	266.6	8.8	Net income, 39.5; Payment for dividends, (22.4)
Treasury stock, at cost	**(0.5)**	**(0.1)**	(0.5)	0.0	
Accumulated other comprehensive loss	**13.0**	**1.4**	(1.2)	14.2	
Unrealized holding (losses) gains on securities	**14.9**	**1.6**	8.7	6.2	
Deffered (losses) gains on hedges	**0.1**	**0.0**	0.5	(0.4)	
Translation adjustments	**0.1**	**0.0**	(2.4)	2.5	
Remeasurements of defined benefit plans	**(2.2)**	**(0.2)**	(8.1)	5.9	
Minority interests	**11.5**	**1.2**	11.8	(0.3)	

*1: Notes and accounts receivable = Bills + Accounts receivable

*2: Notes and account payable=Bills(except non-operating bills)+Accounts payable

(2) Cash Flow Statement

[Billion yen]

	FY2014	FY2013	Increase (Decrease)
Cash and cash equivalents at beginning of year	**85.0**	58.7	26.2
Cash flows from operating activities	**68.2**	69.9	(1.7)
Income before income taxes and minority interests	**62.7**	72.4	(9.8)
Depreciation and amortization	**9.0**	9.1	(0.1)
Impairment loss	**2.6**	1.4	1.2
Amortization of goodwill	**14.4**	10.6	3.8
Increase (decrease) in accrued retirement benefit for employees	**-**	(9.4)	9.4
Increase (decrease) in net defined benefit liability	**(0.5)**	7.9	(8.4)
Decrease (increase) in prepaid pension expenses	**-**	36.9	(36.9)
Decrease (increase) in net defined benefit asset	**(3.9)**	(34.5)	30.6
Increase (decrease) in reserve for HCV litigation	**(0.6)**	(1.0)	0.4
Interest and dividend income	**(2.4)**	(2.4)	0.0
Loss (gain) on sales of shares of subsidiaries and affiliates	**(0.6)**	-	(0.6)
Loss (gain) on sales and disposal of fixed assets	**(11.8)**	(0.7)	(11.1)
Restructuring expenses	**12.3**	-	12.3
Profit on arbitration award	**-**	(11.0)	11.0
Loss (gain) on step acquisitions	**-**	(0.9)	0.9
Loss (gain) on sale of investment in securities	**(1.0)**	(2.4)	1.4
Loss (gain) on valuation of investment in securities	**0.1**	0.6	(0.5)
Equity in losses (earnings) of affiliates	**0.0**	(0.6)	0.6
Decrease(increase) in notes and accounts receivable-trade	**(6.7)**	6.6	(13.3)
Decrease (increase) in inventories	**7.8**	(0.7)	8.5
Decrease(increase) in notes and accounts payable, trade	**0.5**	(4.1)	4.6
Increase(decrease) in accounts payable, other	**5.9**	0.8	5.1
Interest and dividends received	**2.4**	3.5	(1.1)
Proceeds from arbitration award	**-**	12.2	(12.2)
Income taxes paid	**(20.0)**	(28.1)	8.2
Other, net	**(2.1)**	3.7	(5.8)
Cash flows from investing activities	**(59.8)**	(24.3)	(35.5)
Purchase/sales etc. of marketable securities	**(26.4)**	22.4	(48.8)
Increase/decrease in time deposits	**(20.2)**	(1.9)	(18.3)
Increase in deposits	**(20.6)**	(20.7)	0.1
Purchase/sales of property, plant and equipment	**(1.3)**	(9.4)	8.1
Purchase of intangible fixed assets	**(1.5)**	(2.0)	0.5
Purchase/sales of investment in securities	**1.1**	8.9	(7.8)
Purchase of investment in subsidiaries	**-**	(3.7)	3.7
Proceeds from sales of shares of subsidiaries and associates	**7.6**	-	7.6
Purchase of investment in subsidiaries resulting in consolidation scope change	**-**	(17.9)	17.9
Proceeds from sales of shares of subsidiaries resulting in change in scope of consolidation	**1.5**	-	1.5
Other, net	**0.0**	(0.1)	0.1
Cash flows from financing activities	**(21.9)**	(21.1)	(0.8)
Increase (decrease) in short-term debt, net	**(1.2)**	(0.2)	(1.0)
Increase in long-term debt	**-**	1.0	(1.0)
Proceeds from share issuance to minority shareholders	**2.6**	0.6	2.0
Cash dividends paid	**(22.4)**	(22.4)	-
Cash dividends paid to minority shareholders	**(0.6)**	0.0	(0.5)
Other, net	**(0.2)**	(0.1)	(0.2)
Effect of exchange rate change on cash and cash equivalents	**1.9**	1.8	0.2
Net increase (decrease) in cash and cash equivalents	**(11.6)**	26.2	(37.8)
Cash and cash equivalents at end of the year	**73.3**	85.0	(11.6)

The Reconciliation of Cash and Cash Equivalents in the Consolidated Balance Sheets and Cash and Cash Equivalents in the Consolidated Statements of Cash Flows at the End of the Period [Billion yen]

	FY2014	FY2013
Cash and time deposits	50.2	27.2
Time deposits maturing after three months	(25.6)	(4.8)
Short-term investments in marketable securities maturing within three months of acquisition	28.0	42.0
Cash equivalents included in short-term loans receivable*	0.7	0.6
Cash equivalents included in deposits	20.0	20.0
Cash and cash equivalents in the consolidated statements of cash flows	73.3	85.0

*: Short-term loans are included in "Others, Current Assets" on page 6.

(3) Investment in Property, Plant and Equipment and Investment in Development of Information Systems

[Billion yen]

	FY2014	FY2013	Increase (Decrease)
Investment in property, plant and equipment / occuring basis	15.7	12.6	3.1
Investment in information systems/ occuring basis	1.6	2.1	(0.5)

[Billion yen]

Major investment in property, plant and equipment in FY2014		Major investment in development of information systems in FY2014	
Mitsubishi Tanabe Pharma	9.3	Mitsubishi Tanabe Pharma	1.3
[Construction of new head office and Kashima office building]	[5.9]		
Mitsubishi Tanabe Pharma Factory	4.0		
[Construction of new manufacturing facility at Yoshitomi plant]	[1.8]		

(4) Depreciation Costs

[Billion yen]

	FY2014	FY2013	Increase (Decrease)
Property, plant and equipment	7.5	7.9	(0.4)
Intangible fixed assets	1.6	1.3	0.3

3. Financial Data & Employee Numbers of Major Consolidated Subsidiaries

[Billion yen]

	Companies	Mitsubishi Tanabe Pharma Factory Ltd.	Tanabe Seiyaku Hanbai Co., Ltd.	Mitsubishi Tanabe Pharma Korea Co., Ltd.	Medicago, Inc.	Tianjin Tanabe Seiyaku Co., Ltd.	P.T. Tanabe Indonesia
Net sales	FY2014	39.4	13.6	4.4	1.1	4.5	2.3
	FY2013	47.2	14.1	4.1	0.0	3.6	2.3
Operating income	FY2014	3.6	(0.1)	0.2	(5.1)	0.5	0.1
	FY2013	1.2	0.4	0.3	(1.3)	0.1	0.3
Ordinary income	FY2014	3.6	(0.1)	0.3	(5.2)	0.5	0.1
	FY2013	1.1	0.4	0.4	(1.2)	0.1	0.3
Net income	FY2014	0.7	(0.1)	0.2	(5.3)	0.3	0.0
	FY2013	0.7	0.3	0.3	(1.2)	0.0	0.2
R&D expenses	FY2014	1.3	-	-	6.2	0.2	0.0
	FY2013	1.2	-	-	1.4	0.0	0.0
Depreciation of property, plant and equipment	FY2014	2.2	0.0	0.1	0.4	0.1	0.1
	FY2013	2.4	0.0	0.1	0.1	0.1	0.1
Total assets	End of FY2014	48.2	6.0	3.7	35.6	6.1	3.1
	End of FY2013	57.6	6.3	3.3	36.5	4.4	3.6
Net assets	End of FY2014	36.9	0.3	3.0	24.2	3.9	1.7
	End of FY2013	39.8	0.5	2.6	24.1	3.0	1.6
Number of employees	End of FY2014	1,087	168	121	263	537	441
	End of FY2013	1,394	172	125	189	456	480

Note: Prior to elimination of internal transaction

3 Forecasts for FY2015 Ending March 31, 2016

(Amounts less than ¥100 million are rounded.)

(1) Consolidated Forecasts of Profit and Loss

[Billion yen]

	1st Half of FY2015 Forecasts	1st Half of FY2014 Actual	Increase (Decrease)	Change %	FY2015 Forecasts	FY2014 Actual	Increase (Decrease)	Change %	Notes
Net Sales	191.5	198.9	(7.4)	(3.7)	396.0	415.1	(19.1)	(4.6)	Overseas sales ratio FY2014: 18.8% FY2015 estimation: 23.9% Exchange rate planned: 1US$=¥120
Domestic	144.3	165.0	(20.7)	(12.5)	301.5	337.2	(35.7)	(10.6)	
Overseas	47.2	33.9	13.3	39.3	94.5	77.9	16.6	21.2	
Cost of Sales	70.5	78.2	(7.7)	(9.8)	147.0	169.6	(22.6)	(13.3)	
Sales cost ratio	36.8%	39.3%			37.1%	40.9%			
Gross Operatin Profit	121.0	120.7	0.3	0.2	249.0	245.5	3.5	1.4	
SG & A Expenses	93.0	85.8	7.2	8.5	181.5	178.4	3.1	1.7	
% of Net Sales	48.6%	43.1%			45.8%	43.0%			
Operating Income	28.0	35.0	(7.0)	(19.9)	67.5	67.1	0.4	0.5	
Ordinary Income	28.0	35.5	(7.5)	(21.0)	67.0	67.7	(0.7)	(1.0)	
Extraordinary Income and loss	0.0	10.9	(10.9)	-	(7.5)	(5.0)	(2.5)	-	
Net Income	19.0	32.5	(13.5)	(41.6)	40.5	39.5	1.0	2.5	

(2) Forecasts of Cost of Sales and SG&A Expenses

[Billion yen]

	1st Half of FY2015 Forecasts	1st Half of FY2014 Actual	Increase (Decrease)	Change %	FY2015 Forecasts	FY2014 Actual	Increase (Decrease)	Change %	
Cost of Sales	70.5	78.2	(7.7)	(9.8)	147.0	169.6	(22.6)	(13.3)	
Sales cost ratio	36.8%	39.3%			37.1%	40.9%			
SG & A Expenses	93.0	85.8	7.2	8.5	181.5	178.4	3.1	1.7	
% of Net sales	48.6%	43.1%			45.8%	43.0%			
R&D Expenses	39.5	31.9	7.6	23.7	74.0	69.6	4.4	6.3	
% of Net sales	20.6%	16.1%			18.7%	16.8%			
Except R&D Expenses	53.5	53.8	(0.3)	(0.6)	107.5	108.8	(1.3)	(1.2)	
Labor Cost	23.0	23.0	0.0	(0.1)	46.0	46.8	(0.8)	(1.6)	
Amortization of Goodwill	5.3	5.4	(0.1)	(1.8)	10.5	10.9	(0.4)	(3.8)	
Others	25.2	25.4	(0.2)	(0.8)	51.0	51.1	(0.1)	(0.2)	
Total Labor Cost	38.2	39.8	(1.6)	(4.1)	77.0	81.1	(4.1)	(5.0)	

(3) Sales Forecasts for Main Products [Billion yen]

	1st Half of FY2015 Forecasts	1st Half of FY2014 Actual	Increase (Decrease)	Change %	FY2015 Forecasts	FY2014 Actual	Increase (Decrease)	Change %
Ethical drugs	**189.2**	196.5	(7.3)	(3.7)	**391.6**	410.7	(19.1)	(4.6)
Ethical drugs domestic sales	**140.8**	155.2	(14.4)	(9.3)	**294.6**	323.9	(29.3)	(9.0)
Remicade	**35.6**	35.2	0.4	1.0	**70.7**	70.6	0.1	0.1
Talion	**6.4**	6.1	0.3	5.3	**17.1**	16.0	1.1	7.0
Ceredist	**7.1**	7.9	(0.8)	(10.1)	**14.1**	15.7	(1.6)	(10.0)
Simponi	**6.2**	5.0	1.2	23.1	**13.3**	10.5	2.8	27.2
Maintate	**6.6**	7.2	(0.6)	(7.7)	**13.2**	14.1	(0.9)	(6.7)
Lexapro	**4.1**	3.4	0.7	20.2	**10.5**	8.0	2.5	31.6
Tenelia	**4.5**	2.7	1.8	68.8	**9.6**	6.2	3.4	54.2
Kremezin	**4.8**	5.4	(0.6)	(11.4)	**9.3**	10.5	(1.2)	(11.7)
Urso	**4.6**	5.1	(0.5)	(9.6)	**8.8**	10.0	(1.2)	(11.9)
Depas	**3.4**	4.1	(0.7)	(16.9)	**6.8**	8.1	(1.3)	(15.7)
Anplag	**3.0**	4.4	(1.4)	(31.1)	**5.8**	8.3	(2.5)	(30.0)
Radicut	**2.9**	3.8	(0.9)	(23.6)	**5.4**	7.4	(2.0)	(26.9)
BIKEN products [vaccine]	**10.6**	11.1	(0.5)	(4.5)	**26.9**	30.3	(3.4)	(11.1)
Influenza	**0.6**	0.9	(0.3)	(32.4)	**7.9**	7.4	0.5	7.0
Tetrabik	**3.4**	3.6	(0.2)	(4.6)	**7.1**	7.5	(0.4)	(5.6)
Tanabe Seiyaku Hanbai products *1	**6.9**	6.4	0.5	7.1	**14.4**	13.6	0.8	5.9
Ethical drugs overseas sales	**13.4**	11.3	2.1	18.2	**24.4**	23.0	1.4	5.9
Herbesser	**3.4**	3.5	(0.1)	(1.8)	**6.8**	6.5	0.3	5.1
Argatroban (Novastan)	**1.0**	1.3	(0.3)	(20.4)	**2.5**	2.1	0.4	17.5
Tanatril	**0.8**	1.0	(0.2)	(22.3)	**1.7**	1.8	(0.1)	(7.3)
Contracted manufacturing products *2	**1.1**	2.1	(1.0)	(47.1)	**2.4**	3.4	(1.0)	(28.8)
Royalty income, etc.	**33.9**	27.9	6.0	21.7	**70.2**	60.4	9.8	16.3
Royalty from Gilenya	**Undisclosed**	18.8	-	-	**Undisclosed**	43.9	-	-
Royalty from INVOKANA	**Undisclosed**	Undisclosed	-	-	**Undisclosed**	9.8	-	-
OTC products	**2.1**	2.2	(0.1)	(3.8)	**4.0**	4.0	0.0	0.1
Total pharmaceuticals	**191.5**	198.9	(7.4)	(3.7)	**396.0**	415.1	(19.1)	(4.6)

*3: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*4:Active pharmaceutical ingredients and others ordered by other companies.

(4) Forecasts of Investment for Property, Plant and Equipment and Information Systems

[Billion yen]

	1st Half of FY2015 Forecasts	1st Half of FY2014 Actual	Increase (decrease)	Change %	FY2015 Forecasts	FY2014 Actual	Increase (decrease)	Change %
Investment in property, plant and equipment/occuring basis	4.1	6.2	(2.1)	(33.7)	10.3	15.7	(5.4)	(34.6)
Investment for information systems/occuring basis	1.2	0.8	0.4	56.3	2.1	1.6	0.5	32.4

[Billion yen]

Major investment in property, plant and equipment in FY2015		Major investment for information systems in FY2015	
Production facilities	6.1	R&D related systems	0.6
Facilities & equipment for R&D	3.2	Production related system	0.2
Others	1.0	Others	1.3

(5) Forecasts for Depreciation Costs

[Billion yen]

	1st Half of FY2015 Forecasts	1st Half of FY2014 Actual	Increase (decrease)	Change %	FY2015 Forecasts	FY2014 Actual	Increase (decrease)	Change %
Property, plant and equipment	3.5	3.7	(0.2)	(5.0)	7.2	7.5	(0.3)	(3.7)
Intangible fixed assets	0.8	0.8	0.0	2.4	1.6	1.6	0.0	3.2

4 Five-Year Financial Data

(Amounts less than ¥100 million are rounded.)

(1) Profit and Loss

[Billion yen]

	FY2010	FY2011	FY2012	FY2013	FY2014	Forecast for FY2015
Net sales	409.5	407.2	419.2	412.7	415.1	396.0
Cost of sales	154.6	152.3	166.4	169.4	169.6	147.0
Gross operation profit	255.0	254.9	252.8	243.3	245.5	249.0
SG&A expenses	178.4	185.8	183.8	184.2	178.4	181.5
R&D expenses	65.8	70.2	66.5	70.4	69.6	74.0
Operating income	76.6	69.0	69.0	59.1	67.1	67.5
Ordinary income	76.7	68.8	69.4	61.9	67.7	67.0
Extraordinaly income	0.6	1.2	4.2	15.3	13.7	(7.5)
Extraordinaly loss	13.2	6.1	5.9	4.8	18.6	
Net income	37.7	39.0	41.9	45.4	39.5	40.5

(2) Balance Sheet

[Billion yen]

	End of FY2010	End of FY2011	End of FY2012	End of FY2013	FY2014
Total assets	818.7	819.9	866.8	886.5	929.3
Current assets	391.6	419.7	476.7	540.5	603.6
Fixed assets	427.1	400.3	390.1	346.0	325.7
Total liabilities	122.7	98.4	113.9	108.6	128.9
Current liabilities	87.7	69.6	86.1	81.8	105.4
Fixed liabilities	35.0	28.9	27.7	26.8	23.5
Net assets	696.0	721.5	752.9	777.8	800.4

(3) Other Financial Data

[Billion yen]

	End of FY2010	End of FY2011	FY2012	FY2013	FY2014	Forecast for FY2015
Cash flows from operating activities	59.1	37.2	60.6	69.9	68.2	-
Cash flows from investing activities	(7.7)	(63.2)	(35.0)	(24.3)	(59.8)	-
Cash flows from financing activities	(15.4)	(17.2)	(23.7)	(21.1)	(21.9)	-
Investments in property, plant and equipment	10.2	7.1	9.2	12.6	15.7	10.3
Investments for development of information systems	0.8	1.2	2.2	2.1	1.6	2.1
Depreciation costs	12.4	12.5	8.4	9.2	9.0	8.8
Equity ratio (%)	84.3	87.3	86.3	86.4	84.9	-
ROE (%)	5.5	5.5	5.7	6.0	5.1	-
Net income per share (¥)	67.27	69.54	74.67	80.92	70.41	72.19
Net assets per share (¥)	1,230.16	1,275.85	1,333.22	1,365.52	1,406.41	-

(4) Number of Employees

	End of FY2010	End of FY2011	End of FY2012	End of FY2013	End of FY2014	Forecast for End of FY2015
Consolidated	9,198	9,180	8,835	9,065	8,457	8,359
Non-consolidated	4,957	4,826	4,850	4,867	4,844	4,838

5 Quarterly Trend

(Amounts less than ¥100 million are rounded.)

(1) Profit and Loss

[Billion yen]

	FY2013					FY2014					FY2015
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full year Actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full year Actual	Forecasts for full-year
Net sales	103.9	98.9	120.4	89.5	412.7	94.6	104.3	120.9	95.3	415.1	396.0
	25.2%	24.0%	29.2%	21.7%	100.0%	22.8%	25.1%	29.1%	23.0%	100.0%	
Domestic	91.4	85.3	103.3	73.4	353.3	79.8	85.3	98.6	73.6	337.2	301.5
	25.9%	24.1%	29.2%	20.8%	100.0%	23.7%	25.3%	29.2%	21.8%	100.0%	
Overseas	12.5	13.7	17.1	16.1	59.4	14.8	19.1	22.3	21.7	77.9	94.5
	21.0%	23.0%	28.8%	27.1%	100.0%	19.0%	24.5%	28.7%	27.9%	100.0%	
Cost of sales	43.5	38.9	50.6	36.4	169.4	39.2	39.0	49.8	41.6	169.6	147.0
Sales Cost Ratio	41.9%	39.3%	42.0%	40.7%	41.0%	41.4%	37.4%	41.2%	43.6%	40.9%	37.1%
Gross operating profit	60.4	60.0	69.8	53.1	243.3	55.4	65.3	71.0	53.8	245.5	249.0
	24.8%	24.7%	28.7%	21.8%	100.0%	22.6%	26.6%	28.9%	21.9%	100.0%	
SG&A expenses	44.2	45.8	44.8	49.5	184.2	41.7	44.1	42.4	50.2	178.4	181.5
	24.0%	24.9%	24.3%	26.9%	100.0%	23.4%	24.7%	23.8%	28.2%	100.0%	
R&D expenses	17.6	16.7	17.1	19.0	70.4	16.3	15.6	16.2	21.5	69.6	74.0
	24.9%	23.8%	24.3%	27.0%	100.0%	23.5%	22.4%	23.2%	30.9%	100.0%	
Non-R&D expenses	26.6	29.1	27.7	30.5	113.8	25.3	28.5	26.3	28.7	108.8	107.5
	23.4%	25.6%	24.3%	26.8%	100.0%	23.3%	26.2%	24.1%	26.4%	100.0%	
Labor costs	11.9	12.0	12.4	12.1	48.4	11.1	11.9	11.8	12.0	46.8	46.0
	24.5%	24.8%	25.6%	25.1%	100.0%	23.8%	25.5%	25.2%	25.6%	100.0%	
Amortization of goodwill	2.6	2.7	2.6	2.8	10.6	2.7	2.7	2.7	2.8	10.9	10.5
	24.5%	25.0%	24.5%	26.0%	100.0%	24.7%	24.7%	24.7%	25.8%	100.0%	
Others	12.1	14.4	12.7	15.6	54.8	11.5	13.9	11.8	13.9	51.1	51.0
	22.2%	26.3%	23.1%	28.4%	100.0%	22.6%	27.1%	23.1%	27.2%	100.0%	
Operating income	16.2	14.2	25.1	3.6	59.1	13.7	21.3	28.6	3.5	67.1	67.5
	27.5%	24.1%	42.4%	6.1%	100.0%	20.4%	31.7%	42.7%	5.3%	100.0%	
Ordinary income	17.1	15.1	25.6	4.1	61.9	14.6	20.9	28.6	3.6	67.7	67.0
	27.6%	24.5%	41.3%	6.6%	100.0%	21.5%	30.9%	42.3%	5.3%	100.0%	
Net income	10.4	18.1	15.3	1.5	45.4	9.6	22.9	15.8	(8.8)	39.5	40.5
	22.9%	39.9%	33.7%	3.4%	100.0%	24.3%	58.1%	39.9%	(22.3%)	100.0%	

The each figure (excluding Cost of sales) in the lower displays the progress rate.

(2) Sales of Main Products

[Billion yen]

	FY2013					FY2014					FY2015
	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full Year Actual	Q1 Apr. to Jun.	Q2 Jul. to Sep.	Q3 Oct. to Dec.	Q4 Jan. to Mar.	Full Year Actual	Full Year Forecasts
Ethical drugs	102.3	97.3	119.1	88.4	407.2	93.2	103.3	119.8	94.4	410.7	391.6
	25.1%	23.9%	29.3%	21.7%	100.0%	22.7%	25.1%	29.2%	23.0%	100.0%	
Ethical drugs domestic sales	88.5	82.4	100.5	70.2	341.7	77.5	77.7	96.8	71.9	323.9	294.6
	25.9%	24.1%	29.4%	20.5%	100.0%	23.9%	24.0%	29.9%	22.2%	100.0%	
Remicade	19.2	19.9	21.9	15.4	76.3	17.3	17.9	19.3	16.1	70.6	70.7
	25.1%	26.0%	28.7%	20.2%	100.0%	24.6%	25.3%	27.3%	22.8%	100.0%	
Talion	2.7	2.4	4.4	4.2	13.7	3.3	2.8	4.3	5.7	16.0	17.1
	19.9%	17.5%	31.9%	30.7%	100.0%	20.3%	17.7%	26.6%	35.4%	100.0%	
Ceredist	4.7	4.4	5.0	3.6	17.8	4.1	3.8	4.4	3.4	15.7	14.1
	26.5%	24.9%	28.4%	20.2%	100.0%	26.4%	24.0%	27.9%	21.7%	100.0%	
Maintate	4.0	3.8	4.4	3.3	15.5	3.8	3.4	3.8	3.2	14.1	13.2
	25.7%	24.3%	28.6%	21.4%	100.0%	26.7%	23.9%	26.8%	22.6%	100.0%	
Venoglobulin IH	2.9	2.7	3.4	2.1	11.1	2.8	2.8	3.5	2.5	11.6	-
	26.2%	24.6%	30.3%	18.9%	100.0%	24.4%	24.3%	30.1%	21.2%	100.0%	
Simponi	2.1	2.4	2.8	2.1	9.4	2.5	2.6	2.9	2.5	10.5	13.3
	22.1%	25.2%	29.8%	22.9%	100.0%	23.5%	24.6%	27.9%	23.9%	100.0%	
Kremezin	3.2	3.2	3.5	2.6	12.6	2.8	2.6	2.8	2.3	10.5	9.3
	25.8%	25.2%	28.1%	20.9%	100.0%	26.6%	24.9%	26.8%	21.8%	100.0%	
Urso	3.3	3.1	3.5	2.5	12.4	2.7	2.4	2.7	2.2	10.0	8.8
	26.5%	25.0%	28.2%	20.3%	100.0%	26.7%	24.2%	27.0%	22.1%	100.0%	
Anplag	3.1	2.8	3.2	2.1	11.2	2.4	2.0	2.2	1.7	8.3	5.8
	27.7%	24.9%	28.3%	19.1%	100.0%	28.7%	23.9%	27.0%	20.5%	100.0%	
Depas	2.6	2.4	2.7	2.1	9.8	2.1	2.0	2.2	1.8	8.1	6.8
	26.1%	24.7%	27.4%	21.8%	100.0%	25.9%	24.9%	27.1%	22.2%	100.0%	
Lexapro	1.0	1.4	2.3	1.7	6.5	1.7	1.7	2.7	1.8	8.0	10.5
	15.9%	21.8%	35.4%	26.9%	100.0%	21.1%	21.7%	34.3%	22.9%	100.0%	
Radicut	3.0	2.7	3.2	2.1	10.9	2.0	1.8	2.1	1.5	7.4	5.4
	27.1%	25.1%	28.9%	18.9%	100.0%	26.7%	24.7%	28.3%	20.3%	100.0%	
Tenelia	0.0	0.0	0.5	0.3	0.8	1.1	1.6	1.9	1.7	6.2	9.6
	0.1%	3.8%	64.0%	32.1%	100.0%	17.9%	24.9%	30.6%	26.5%	100.0%	
Herbesser	1.9	1.7	1.9	1.4	6.9	1.5	1.3	1.5	1.2	5.5	4.5
	26.9%	24.7%	28.2%	20.2%	100.0%	27.1%	24.3%	27.3%	21.4%	100.0%	
Tanatril	1.7	1.5	1.8	1.2	6.2	1.3	1.1	1.2	1.0	4.6	3.6
	27.4%	24.6%	28.4%	19.6%	100.0%	27.9%	24.3%	27.0%	20.8%	100.0%	
BIKEN products [vaccines]	8.8	5.2	9.6	4.9	28.4	4.9	6.2	14.8	4.4	30.3	26.9
	30.9%	18.3%	33.7%	17.1%	100.0%	16.2%	20.4%	48.8%	14.5%	100.0%	
Tetrabik	2.9	0.5	1.2	2.2	6.7	1.8	1.8	2.1	1.8	7.5	7.1
	43.1%	7.5%	17.3%	32.2%	100.0%	23.6%	23.7%	28.2%	24.4%	100.0%	
Influenza	(0.1)	1.2	6.5	(0.4)	7.2	(0.1)	0.9	7.3	(0.8)	7.4	7.9
	(0.7%)	16.2%	90.6%	(6.1%)	100.0%	(0.7%)	12.7%	99.3%	(11.3%)	100.0%	
Varicella vaccine	1.0	0.9	0.7	1.0	3.6	0.6	1.3	3.5	1.7	7.2	4.4
	28.9%	25.0%	19.3%	26.8%	100.0%	8.7%	18.2%	48.8%	24.3%	100.0%	
Tanabe Seiyaku Hanbai products *1	3.5	3.2	4.1	3.2	14.1	3.4	3.1	3.9	3.3	13.6	14.4
	25.0%	22.5%	29.4%	23.1%	100.0%	24.8%	22.5%	28.6%	24.0%	100.0%	
Ethical drugs overseas sales	5.1	5.3	5.9	5.7	22.0	5.3	6.0	5.5	6.2	23.0	24.4
	23.3%	24.1%	26.9%	25.8%	100.0%	23.0%	26.3%	23.7%	27.1%	100.0%	
Herbesser	1.5	1.3	1.5	1.6	5.8	1.6	1.9	1.4	1.6	6.5	6.8
	25.3%	22.6%	25.1%	26.9%	100.0%	24.4%	29.1%	22.3%	24.2%	100.0%	
Argatroban (Novastan)	0.7	0.7	0.7	0.6	2.7	0.7	0.6	0.5	0.4	2.1	2.5
	24.8%	26.3%	25.3%	23.7%	100.0%	32.5%	26.5%	22.9%	18.1%	100.0%	
Tanatril	0.5	0.4	0.5	0.5	1.8	0.5	0.6	0.4	0.4	1.8	1.7
	25.8%	20.8%	27.2%	26.3%	100.0%	24.7%	31.4%	21.8%	22.1%	100.0%	
Contracted manufacturing products *2	1.5	1.4	1.4	1.5	5.8	0.9	1.2	0.5	0.8	3.4	2.4
	25.9%	24.5%	24.0%	25.6%	100.0%	27.0%	34.6%	15.1%	23.2%	100.0%	
Royalty income, etc.	7.1	8.2	11.3	11.0	37.6	9.5	18.4	17.0	15.5	60.4	70.2
	18.9%	21.8%	30.0%	29.3%	100.0%	15.7%	30.4%	28.2%	25.7%	100.0%	
Royalty from Gilenya	6.5	7.6	9.5	8.6	32.2	7.7	11.1	13.7	11.4	43.9	Undisclosed
	20.1%	23.6%	29.6%	26.6%	100.0%	17.6%	25.3%	31.1%	26.0%	100.0%	
Royalty from INVOKANA	Undisclosed	Undisclosed	Undisclosed	Undisclosed	Undisclosed	Undisclosed	Undisclosed	Undisclosed	3.6	9.8	Undisclosed
	-	-	-	-	-	-	-	-	37.3%	100.0%	
OTC products	1.1	1.3	1.1	0.9	4.5	1.2	1.0	1.0	0.8	4.0	4.0
	25.5%	29.0%	24.4%	21.1%	100.0%	30.4%	24.2%	24.9%	20.4%	100.0%	
Total sales	103.9	98.9	120.4	89.5	412.7	94.6	104.3	120.9	95.3	415.1	396.0
	25.2%	24.0%	29.2%	21.7%	100.0%	22.8%	25.1%	29.1%	23.0%	100.0%	

The each figure in the lower displays the progress rate.

*1: Tanabe Seiyaku Hanbai Products are composed of generic drugs and the long-listed drugs which were transferred from MTPC.

*2 Active pharmaceutical ingredients and others ordered by other companies.

6 State of New Product Development (As of May 8, 2015)

i. New Drugs

Development code (Generic name)	Category (Indications)	Region	Stage	Origin
TA-650 (Infliximab [recombinant])	Anti-human TNFα monoclonal antibody (Crohn's disease, ulcerative colitis, pediatric Crohn's disease, pediatric ulcerative colitis)	Taiwan	Filed (Sep., 2013)	US:Janssen Biotech
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type 2 diabetes mellitus)	Taiwan	Filed (Mar., 2015)	In-house
MP-513 (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Indonesia	Filed (Apr., 2015)	In-house
		Europe	Phase 2	
		US	Phase 1	
MT-4666	α7nACh receptor agonist (Dementia of Alzheimer's type)	Global clinical trial*	Phase 3	US: FORUM Pharmaceuticals
MT-2412 (Teneligliptin, Canagliflozin)	Fixed-dose combination of DPP-4 inhibitor and SGLT2 inhibitor (Type 2 diabetes mellitus)	Japan	Phase 3	In-house
MP-214 (Cariprazine)	Dopamine D3/D2 receptor partial agonist (Schizophrenia)	Japan,Asia	Phase 2b/3	Hungary: Gedeon Richter
MT-3995	Selective mineralocorticoid receptor antagonist (Diabetic nephropathy)	Europe	Phase 2	In-house
		Japan	Phase 2	
		US	Phase 1	
MT-1303	S1P receptor functional antagonist (Multiple sclerosis)	Europe	Phase 2	In-house
	(Psoriasis)	Europe	Phase 2	
	(Inflammatory diseases, autoimmune diseases)	Japan,Europe, US	Phase1	
MT-2301	Haemophilus influenza type b (Hib) vaccine (Prophylaxis of pediatric Hib infection)	Japan	Phase 2	US: Nuron Biotech
Influenza vaccine	Plant-based VLP vaccine (Prophylaxis of H5N1 influenza)	Canada	Phase 2	In-house
Influenza vaccine	Plant-based VLP vaccine (Prophylaxis of seasonal influenza)	US, Canada	Phase 2	In-house
Influenza vaccine	Plant-based VLP vaccine (Prophylaxis of H7N9 influenza)	Canada	Phase 1	In-house
GB-1057 (Recombinant human serum albumin)	Recombinant human serum albumin (Stabilizing agent)	US	Phase 1	In-house
MP-124	PARP inhibitor (Acute ischemic stroke)	US	Phase 1	In-house
MP-157	Angiotensin type 2 receptor agonist (Hypertension)	Europe	Phase 1	In-house
MT-0814	CC chemokine receptor 3 antagonist (Age-related macular degeneration)	Japan	Phase 1	In-house

* Co-developed with FORUM Pharmaceuticals.

ii. Additional Indications

Product name (Generic name)	Category (Indications)	Region	Stage	Origin	Notes
Talion (Bepotastine)	Selective histamine H1 receptor antagonist, anti-allergic agent (Pediatric allergic rhinitis)	Japan	sNDA filed (May, 2014)	Japan: Ube Industries	
	(Pediatric atopic dermatitis)		sNDA filed (May, 2014)		
Radicut (Edaravone)	Free radical scavenger (Amyotrophic lateral sclerosis*)	Japan	sNDA filed (Oct., 2014)	In-house	
Remicade (Infliximab [recombinant])	Anti-human TNFα monoclonal antibody (Behcet's disease with special lesions*)	Japan	sNDA filed (Oct., 2014)	US:Janssen Biotech	
	(Refractory Kawasaki disease*)		Phase 3		
	(Pediatric Crohn's disease)		Phase 3		
	(Pediatric ulcerative colitis)		Phase 3		
	(Psoriasis: increased dose)		Phase 3		
Tribik (Adsorbed diphtheria-purified pertussis-tetanus combined vaccine)	Vaccine (Prophylaxis of pertussis, diphtheria, and tetanus; Stage 2 vaccination)	Japan	sNDA filed (Apr., 2015)	Japan:The Research Foundation for Microbial Diseases of Osaka University	Co-developed with The Research Foundation for Microbial Diseases of Osaka University
Telavic (Telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C, [combination with Feron])	Japan	Phase 3	US:Vertex Pharmaceuticals	
Imusera (Fingolimod)	S1P receptor functional antagonist (Chronic inflammatory demyelinating polyradiculoneuropathy)	Global clinical trial	Phase 3	In-house	Co-developed with Novartis Pharma in Japan, licensed to Novartis overseas
Canaglu (Canagliflozin)	SGLT2 inhibitor (Diabetic nephropathy)	Global clinical trial	Phase 3	In-house	Sponsor: Janssen Research & Development, LLC

* Orphan drug designated

iii. Licensing-out

Development code (Generic name)	Category (Indications)	Region	Stage	Licensee (Notes)
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type2 diabetes mellitus / fixed dose combination with metformin, XR)	US	Phase 3	US: Janssen Pharmaceuticals, Inc
	(Diabetic nephropathy)	Global clinical trial	Phase 3	
FTY720 (Fingolimod)	S1P receptor functional antagonist (Chronic inflammatory demyelinating polyradiculoneuropathy)	Global clinical trial	Phase 3	Switzerland: Novartis (Co-developed with Novartis Pharma in Japan)
Y-39983	ROCK (rho-kinase) inhibitor (Glaucoma)	Japan	Phase 2	Japan: Senju Pharmaceutical
MT-210	5-HT2A/ Sigma 2 receptor antagonist (Schizophrenia)	Europe	Phase 2	US:Minerva Neuroscience
TA-7906	PDE4 inhibitor (Atopic dermatitis)	Japan	Phase 2	Japan: Maruho
MCC-847 (Masilukast)	Leukotriene D4 receptor antagonist (Asthma)	Korea	Phase 2	Korea: SAMA Pharma
TA-8995	CETP inhibitor (Dyslipidemia)	Europe	Phase 2	Netherlands: DEZIMA Pharma
MT-4580	Ca sensing receptor agonist (Secondary hyperparathyroidism in hemodialysis patients)	Japan	Phase 2	Japan: Kyowa Hakko Kirin
sTU-199 (Tenatoprazole)	Proton pump inhibitor (Gastroesophageal reflux disease)	Europe	Phase 1	France: Negma/Sidem
Wf-516	SSRI / 5HT1A receptor antagonists (Depression)	Europe	Phase 1	US:Minerva Neuroscience
Y-803	Bromodomain inhibitor (Hematological cancer)	Europe, Canada	Phase 1	US: Merck* (Development code: OTX015)
	(Solid cancer)	Europe, Canada	Phase 1	

* Merck acquired OncoEthix, the licensee, in December 2014.

iv. Changes Since Previous Announcement on February 2, 2015

In-house Development

Development code/product name (Generic name)	Category (Indications)	Region	As of February 2, 2015	As of May 8, 2015
TA-650 (Infliximab [recombinant])	Anti-human TNFα monoclonal antibody (Crohn's disease, Ulcerative colitis, Pediatric Crohn's disease, Pediatric ulcerative colitis)	Taiwan	None	Filed (Sep., 2013)
TA-7284 (Canagliflozin)	SGLT2 inhibitor (Type 2 diabetes mellitus)	Taiwan	None	Filed (Mar., 2015)
MP-513 (Teneligliptin)	DPP-4 inhibitor (Type 2 diabetes mellitus)	Indonesia	None	Filed (Apr., 2015)
Tribik (Adsorbed diphtheria-purified pertussis-tetanus combined vaccine)	Vaccine (Prophylaxis of pertussis, diphtheria, and tetanus; Stage 2 vaccination)	Japan	Phase 3	sNDA filed (Apr., 2015)
MP-424 (Telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C)	Korea	Phase 1	Discontinued
Telavic (Telaprevir)	NS3-4A protease inhibitor (Chronic hepatitis C, [combination with Pegasys])	Japan	Phase 3	Discontinued
BindRen (Colestilan[INN])	Non-absorbed phosphate binder (Pediatric hyperphosphatemia)	Europe	Phase 3	Discontinued
Cholebine (Colestimide[JAN])	Bile acid signal regulation (Type 2 diabetes mellitus)	Japan	Phase 2	Discontinued
	Non-absorbed phosphate binder (Hyperphosphatemia)		Phase 1	

Licensing-out

Development code (Generic name)	Category (Indications)	Region	As of February 2, 2015	As of May 8, 2015
MP-513 (Teneligliptin)	DPP-4 inhibitor (Type2 diabetes mellitus / fixed dose combination with metformin, XR)	Korea	NDA filed*	Approved (Mar., 2015)
FTY720 (Fingolimod)	S1P receptor functional antagonist (Primary progressive multiple sclerosis)	Global clinical trial	Phase 3	Discontinued

* 20mg/1000mg(teneligliptin/metformin), 10mg/750mg and 10mg/500mg were submitted in Oct., Nov., and Dec. 2014, respectively.

5. Additional Information for State of New Product Development (as of May 8, 2015)

(1) New Drugs

Development code (Generic name)	Information
TA-650 (Infliximab[recombinant])	TA-650 is an anti-human TNFα monoclonal antibody. In Japan, it was launched under the brand name of Remicade® in 2002.
TA-7284 (Canagliflozin)	As a selective SGLT2 inhibitor, TA-7284 decreases blood glucose levels by inhibiting reabsportion of glucose in the kidney. It was launched in Japan for the treatment of type2 diabetes mellitus in September 2014, under the brand name of CANAGLU®.
MP-513 (Teneligliptin)	MP-513 selectively inhibits DPP-4, thus accelerates the insulin secretion after meal intake without effect on the fasting insulin secretion. It was launched in Japan for the treatment of type2 diabetes mellitus in September 2012, under the brand name of TENELIA®.
MT-4666	MT-4666, licensed from FORUM Pharmaceuticals(US), is an α7nACh receptor agonist, which ameliorates cognitive dysfunction by activation of both the cholinergic system and the glutamatergic system. Clinical stage is Phase 3 for dementia of Alzheimer's type. It is a global clinical trial and co-developed with FORUM Pharmaceuticals.
MT-2412	MT-2412 is a fixed-dose combination of Teneligliptin(DPP-4 inhibitor) and Canagliflozin(SGLT2 inhibitor).
MP-214 (Cariprazine)	MP-214 is a dopamine D3/D2 receptor partial agonist, licensed from Gedeon Richter (Hungary). Efficacy on negative symptoms and cognitive functions in addition to positive symptoms for schizophrenia is expected.
MT-3995	MT-3995 is a selective mineralocorticoid receptor antagonist, which shows renoprotective effect on diabetic nephropathy.
MT-1303	MT-1303 is a sphingosine-1-phosphate receptor functional antagonist, which keeps lymphocytes sequestered in the lymph nodes and prevents them from contributing to autoimmune reactions. It's a successor of Imusera/Gilenya.
MT-2301	MT-2301 is a Haemophilus influenza type b (Hib) vaccine, licensed from Nuron Biotech(US).
Influenza vaccine	Plant-based VLP influenza vaccine for prophylaxis of H5N1 influenza.
Influenza vaccine	Plant-based VLP influenza vaccine for prophylaxis of seasonal influenza.
Influenza vaccine	Plant-based VLP influenza vaccine for prophylaxis of H7N9 influenza.
GB-1057(Recombinant human serum albumin)	GB-1057 is a recombinant human serum albumin.
MP-124	MP-124 is a PARP inhibitor that has neuroprotective effect.
MP-157	MP-157 is an angiotensin type2 receptor agonist.
MT-0814	MT-0814 is a CC chemokine receptor 3 antagonist.

(2) Additional Indications

Product name (Generic name)	Information
Talion (Bepotastine)	Talion is a selective histamine H1 receptor antagonist. It was launched as an anti-allergic agent for adult in 2000.
Radicut (Edaravone)	Radicut is a free radical scavenger. In 2001, it was launched for improvement neurological symptoms at the acute stage of cerebral infarction, interference with activities of daily living and functional disability.
Remicade (Infliximab[recombinant])	Remicade is an anti-human TNFα monoclonal antibody. In Japan, it was launched as a treatment for Crohn's disease in 2002, followed by rheumatoid arthritis, intractable uveoretinitis caused by Behcet's disease, psoriasis, ankylosing spondylitis, and ulcerative colitis.
Tribik (Adsorbed diphtheria-purified pertussis-tetanus combined vaccine)	Tribik is a diphtheria-purified pertussis-tetanus combined vaccine. It has been jointly developed with the Research Foundation for Microbial Diseases of Osaka University.
Telavic (Telaprevir)	Telavic was launched in Japan for the treatment of chronic hepatitis C (genotype1) in 2011, followed by Chronic hepatitis C (genotype2) in September, 2014.
Imusera (Fingolimod)	Imusera is a sphingosine-1-phosphate receptor functional antagonist, which keeps lymphocytes sequestered in the lymph nodes and prevents them from attacking the myelin of the nerve cells in multiple sclerosis. It was launched as a treatment for multiple sclerosis in 2011 in Japan. Imusera had been jointly developed with Novaltis Pharma for the domestic market. Global Phase 3 study for chronic inflammatory demyelinating polyradiculoneuropathy is underway. It has been jointly developed with Novartis Pharma for the domestic market.
CANAGLU (Canagliflozin)	As a selective SGLT2 inhibitor, CANAGLU decreases blood glucose levels by inhibiting reabsportion of glucose in the kidney. It was launched in Japan for the treatment of type2 diabetes mellitus in September, 2014. It was launched for the treatment of type2 diabetes mellitus under the brand name of INVOKANA® by Janssen Pharmaceuticals, Inc. in the US and its affiliate in Europe.

(3) Licensing-out

Development code (Generic name)	Information
TA-7284 (Canagliflozin)	As a selective SGLT2 inhibitor, TA-7284 decreases blood glucose levels by inhibiting reabsorption of glucose in the kidney. It was launched for the treatment of type2 diabetes mellitus under the brand name of INVOKANA® by Janssen Pharmaceuticals, Inc. in the US and its affiliate in Europe. The fixed dose combination with metformin (IR) was approved in Europe (April, 2014) and the US (August, 2014).
FTY720 (Fingolimod)	Sphingosine-1-phosphate receptor functional antagonist. It was launched as a treatment for multiple sclerosis under the brandname of Imusera by Mitsubishi Tanabe Pharma in Japan. It is also marketed under the brand name of Gilenya by Novartis.
Y-39983	Y-39983 is a ROCK (Rho-kinase) inhibitor, which relaxes vascular smooth muscles.
MT-210	MT-210 is a 5-HT2A/ Sigma 2 receptor antagonist.
TA-7906	TA-7906 is a PDE4 inhibitor.
MCC-847 (Masilukast)	MCC-847 is a Leukotriene D4 receptor antagonist.
TA-8995	TA-8995 is a CETP inhibitor, which raises HDL-C levels and lowers LDL-C levels.
MT-4580	MT-4580 is a Ca sensing receptor agonist.
sTU-199 (Tenatoprazole)	sTU-199 is an isomer of TU-199, developed in Japan, and licensed to Negma (France). Pharmacokinetic/pharmacodynamic results from Phase 1 in Europe and the US demonstrated that sTU-199 controlled gastric acid secretion at nighttime in patients receiving this compound once-daily, with the long half-life. It is expected that this compound could reveal rapid improvement for non-erosive reflux disease.
Wf-516	Wf-516 is a SSRI / 5HT1A receptor antagonists.
Y-803	Y-803 is a Bromodomain inhibitor.

7 Others

1 Subsidiaries and Affiliated Companies

(1) Number of Subsidiaries and Affiliated Companies

	End of FY2014	End of FY2013	Increase (Decrease)	Notes
Consolidated subsidiaries	28	31	(3)	Decrease: Mitsubishi Pharma (Guangzhou), Benesis, Mitsubishi Tanabe Pharma America
Non-consolidated subsidiaries	1	2	(1)	Decrease: CMIC CMO Ashikaga
Affiliated companies	1	5	(4)	Decrease: API Corporation, Arkema Yoshitomi, Mapic Europe, Mapic India
Total	30	38	(8)	

(2) Consolidated Subsidiaries [As of March 31, 2015]

	Company Name	Paid-in Capital	% Voting Control [% Indirect Ownership]		Settling Day	Description of Business
1	Mitsubishi Tanabe Pharma Factory Ltd.	JPY 1,130 million	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
2	Mitsubishi Tanabe Pharma Korea Co., Ltd.	KRW 2,100,000,000	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
3	Tianjin Tanabe Seiyaku Co., Ltd.	USD 16,230,000	75.4	[-]	End of Dec.	Manufacture and sale of pharmaceuticals
4	Yoshitomiyakuhin Corporation	JPY 385 million	100.0	[-]	End of Mar.	Provision of information about pharmaceuticals
5	Bipha Corporation	JPY 100 million	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
6	Tanabe Seiyaku Yoshiki Factory Co., Ltd.	JPY 400 million	100.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
7	Tanabe Seiyaku Hanbai., Ltd.	JPY 169 million	100.0	[-]	End of Mar.	Sale of generic pharmaceuticals, etc.
8	Tanabe R&D Service Co., Ltd.	JPY 44 million	100.0	[-]	End of Mar.	Support of R&D regarding pharmaceuticals
9	Tanabe Total Service Co., Ltd.	JPY 90 million	100.0	[-]	End of Mar.	Real estate management and creation of promotion materials, etc.
10	MP Healthcare Venture Management, Inc.	USD 100	100.0	[100.0]	End of Mar.	Investments in bio-ventures
11	Mitsubishi Tanabe Pharma Holdings America, Inc.	USD 167	100.0	[-]	End of Mar.	Management of group companies in US
12	Mitsubishi Tanabe Pharma Development America, Inc.	USD 100	100.0	[100.0]	End of Mar.	R&D of pharmaceuticals
13	Tanabe Research Laboratories U.S.A., Inc.	USD 3,000,000	100.0	[100.0]	End of Mar.	R&D of pharmaceuticals
14	MTPC Holdings Canada Inc.	CAD 242 million	100.0	[-]	End of Mar.	Investments in Medicago Group
15	Medicago Inc.	CAD 253 million	60.0	[55.9]	End of Mar.	Manufacture and sale of vaccines
16	Medicago USA Inc.	USD 99	60.0	[60.0]	End of Mar.	Manufacture of vaccines
17	Medicago R&D Inc.	CAD 500	60.0	[60.0]	End of Mar.	R&D of vaccines
18	Mitsubishi Tanabe Pharma Development (Beijing) Co., Ltd.	USD 1,000,000	100.0	[-]	End of Dec.	R&D of pharmaceuticals
19	Guangdong Tanabe Pharmaceutical Co., Ltd.	CNY 7,000,000	100.0	[-]	End of Dec.	Sale of pharmaceuticals
20	Taiwan Tanabe Seiyaku Co., Ltd.	TWD 90,000,000	65.0	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
21	Tai Tien Pharmaceuticals Co., Ltd.	TWD 20,000,000	65.0	[-]	End of Mar.	Sale of pharmaceuticals
22	P.T. Tanabe Indonesia	USD 2,500,000	99.6	[-]	End of Mar.	Manufacture and sale of pharmaceuticals
23	Mitsubishi Tanabe Pharma Europe Ltd.	GBP 4,632,000	100.0	[-]	End of Mar.	R&D of pharmaceuticals
24	Mitsubishi Tanabe Pharma GmbH	EUR 25,000	100.0	[100.0]	End of Mar.	Sale of pharmaceuticals

Note: Aside from the companies mentioned above, there are four consolidated companies under the liquidations.

(3) Affiliated Companies Accounted for by the Equity Method [As of March 31, 2015]

	Company Name	Paid-in Capital (Million yen)	% Voting Control [% Indirect Ownership]		Settling Day	Description of Business
1	Synthelabo-Tanabe Chimie S.A.	EUR 1,600,000	50.0	[-]	End of Dec.	Manufacture and sale of pharmaceuticals

2 Status of Shareholders

(1) Number of Outstanding Shares

	End of March, 2015	End of March, 2014
Issued	**561,417,916**	561,417,916
The company's own shares at the end of the period	**428,340**	426,862
Number of shares outstanding at the end of the period	**560,989,576**	560,991,054
Average number of the company's own share in the period	**427,456**	425,775
Average number of shares outstanding in the period	**560,990,460**	560,992,141

(2) Status of Major Shareholders

Rank	Name of Shareholders	End of March, 2015		End of March, 2014		
		Number of Shares (Thousands)	Percentage of Total	Rank	Number of Shares (Thousands)	Percentage of Total
1	Mitsubishi Chemical Holdings Corporation	316,320	56.34%	1	316,320	56.34%
2	The Master Trust of Japan, Ltd.	24,137	4.30%	2	22,305	3.97%
3	Nippon Life Insurance Company	12,065	2.15%	3	13,574	2.42%
4	Japan Trustee Services Bank, Ltd.	10,669	1.90%	4	9,406	1.68%
5	The Bank of Tokyo-Mitsubishi UFJ, Ltd.	7,254	1.29%	5	7,254	1.29%
6	STATE STREET BANK AND TRUST COMPANY 505225	5,488	0.98%	10	4,432	0.79%
7	Employee Stock Ownship Plan	4,505	0.80%	9	4,779	0.85%
8	STATE STREET BANK CLIENT OMNIBUS OM04	4,172	0.74%	56	921	0.16%
9	Nipro Corporation	3,821	0.68%	13	3,821	0.68%
10	STATE STREET BANK WEST CLIENT-TREATY 505234	3,635	0.65%	17	2,767	0.49%

(3) Ownership and Distribution of Shares

	End of March, 2015			End of March, 2014		
	Number of Shareholders	Number of Shares (Thousands)	Percentage of Total	Number of Shareholders	Number of Shares (Thousands)	Percentage of Total
Financial institutions	75	98,321	17.52%	77	85,620	15.25%
Foreign corporations and others	465	100,650	17.93%	402	110,839	19.75%
Individuals and others	13,972	24,578	4.38%	16,660	28,217	5.03%
Other corporations	251	334,680	59.62%	270	334,919	59.67%
Securities firms	34	3,083	0.55%	28	1,716	0.31%
Total	14,797	561,315	100.00%	17,437	561,314	100.00%
Less than trading unit	-	102	-	-	103	-

* The trading unit of the Company's stock is 100 shares.

* Individuals and Others include treasury stocks (428 thousands shares at the end of March, 2015 and 426 thousands shares at the end of March, 2014)

(4) Trend of Divinded and Stock Price

	FY2010	FY2011	FY2012	FY2013	FY2014	FY2015 Estimate
Dividends per share (yen)	28	35	40	40	42	44
Dividend payout ratio(%)	41.6	50.3	53.6	49.4	59.6	60.9
(prior to amortization of goodwill)	(32.9)	(40.0)	(43.2)	(40.5)	(47.6)	(48.8)
Stock price at the end of FY	1,350	1,161	1,445	1,443	2,062	-
Market capitalization (billion yen)	7,579	6,518	8,112	8,101	11,576	-

Reference

Major Ethical Drugs

Remicade (Infliximab)	Launch: May 2002	Category	Anti-TNFα monoclonal antibody

Remicade is an anti-TNFα antibody, which targets TNFα, an important inflammatory cytokine. It is very fast-acting and its efficacy is sustained for eight weeks with a single administration. It has indications for the treatment of rheumatoid arthritis, Crohn's disease, Behcet's disease with refractory uveoretinitis, psoriasis, ankylosing spondylitis, and ulcerative colitis. In addtion, in July 2009 and August 2011, changes in usage/dosage were approved for rheumatoid arthritis, and Crohn's disease, respectively.
Origin: Janssen Biotech

Talion (Bepotastine)	Launch: Oct. 2000	Category	Agent for treatment of allergic disorders

Talion has rapid onset of anti-histamine(H1) effects and has been demonstrated to be effective for allergic rhinitis, urticaria, and pruritus accompanying dermatitis. It has minimal incidence of sedation. An additional formulation, orally disintegrating tablets, was approved in March and launched in July 2007.
Origin: Ube Industries

Ceredist (Taltirelin)	Launch: Sep. 2000	Category	Agent for treatment of spinocerebellar degeneration

Thyrotropin releasing hormone (TRH) was known to be effective against ataxia caused by spinocerebellar degeneration, but it was previously administered only through injection. Ceredist, developed by Tanabe, is the world's first oral TRH derivative drug. An additional formulation, orally disintegrating tablets, was launched in October 2009.

Maintate (Bisoprolol)	Launch: Nov. 1990	Category	Selective β1 antagonist (Treatment of hypertension, angina pectoris, and arrhythmias)

Maintate is a representative β-blocker used in more than 100 countries around the world. It exhibits high selectivity for β1 receptor and excellent phamacokinetics profiles. It has high efficacy and safety, and evidence-based cardioprotective action. In addition to the indication of chronic heart failure which was approved in May, 2011, the indication of atrial fibrillation has been newly approved in June, 2013 . Maintate is the only β-blocker with both indications of chronic heart failure and atrial fibrillation in Japan.
Origin: Merck Serono (Germany)

Simponi (Golimumab)	Launch: Sep. 2011	Category	Anti-TNFα monoclonal antibody

Simponi is a human anti-TNFα monoclonal antibody for the treatment of rheumatoid arthritis (including prevention of articular structural damage), and co-marketed with Janssen Pharmaceutical. It shows a long acting efficacy by subcutaneous injection once every four weeks, and currently is under development for the ulcerative colitis by Janssen Pharmaceutical.
Origin: Janssen Biotech

Kremezin	Launch: Apr. 2011	Category	Agent for treatment of Chronic renal failure

Kremezin is an oral absorptive charcoal consisting of porous spherical activated carbon of high purity. It absorbs and excretes uremic toxins out of the body. Keremezin was introduced to the Japanese market in December 1991 as the first pharmaceuticals drug in the world for proactive treatment of chronic renal failure (progressive). In April, 2011, the marketing rights were transferred from Daiichi Sankyo to MTPC.
Origin, Manufacturer and distributor: Kureha

Urso (Ursodeoxycholic Acid)	Launch: July 1962	Category	Agent for improving hepatic, biliary and digestive functions

Ursodeoxycholic acid (UDCA), principal ingredient of Urso, had been extracted from blackbear's gallbladder in the past and has been used in the treatment of various digestive diseases. It is one of the bile acids existing in the human body. Urso has effects of hapatic protection and indications of improvement of liver function in chronic liver disease and hepatitis C, and dissolution of gallstones.

Anplag (Sarpogrelate)	Launch: Oct. 1993	Category	5-HT2 blocker (Anti-platelet agent)

Anplag, an oral anti-platelet, is used to patients with arteriosclerosis obliterans (ASO) to improve ischemic symptoms like as ulcer, pain and coldness of limbs associated with chronic arterial occlusion. Anplag especially improves the bloodstream of collateral circulation and inhibits platelet aggregation, vascular contraction and growth of vascular smooth muscle cell by antagonistic action to serotonin receptor in platelets and vessels.

Depas (Etizolam)	Launch: Mar. 1984	Category	Antianxiety agent

Depas is the most widely used anxiolytic agent in Japan. Due to its broad pharmacological properties, Depas shows reasonable effectiveness for psychosomatic disease, neurosis, low back pain, neck pain and muscle-contraction headache, depression and sleep disorder.

Lexapro (Escitalopram)	Launch: Aug. 2011	Category	Selective sertonin reuptake inhibitor (SSRI)
Lexapro, a highly selective serotonin reuptake inhibitor (SSRI), has been globally approved in 98 countries and regions. It shows good efficacy and tolerability in patients with depressive disorder. Moreover, due to simple dosage and administration, it is expected to improve adherence of the treatment. Origin: H. Lundbeck A/S (Denmark), Manufacturer and distributor: Mochida Pharmaceutical Co., Ltd			
Radicut (Edaravone)	Launch: Jun. 2001	Category	Free radical scavenger (Cerebral neuroprotectant)
Radicut is the world's first brain protecting agent (free radical scavemger) shown to improve neurological symptoms, interference with activities of daily living, and disability (at hospital discharge) in patients at acute stage of cerebral infarction. Specific indications include the treatment of various types of infarction (cerebral lacunar, atherothrombotic and cardiogenic infarction) It is initiated administration within 24 hours after onset, and is not administrated for more than 14 days. An additional formulation, Radicut bag for I.V. Infusion, was launched in May 2010.			
Tenelia (Teneligliptin)	Launch: Sep. 2012	Category	Selective DPP-IV inhibitor
Tenelia, which Mitsubishi Tanabe has created and developed, is the first DPP-4 inhibitor originating in Japan that has ever been launched. It inhibits the function of dipeptidyl peptidase-4 (DPP-4), which selectively breaks down glucagon-like peptide-1(GLP-1), a hormone secreted from the gastrointestinal tract in response to food intake. In this way, Tenelia promotes insulin secretion and suppresses glucagon secretion, thereby demonstrating blood glucose lowering action.			
Herbesser (Diltiazem)	Launch: Feb. 1974	Category	Calcium antagonist (Treatment of angina pectoris and hypertension)
Herbesser is a representative calcium antagonist that is used in more than 110 countries around the world. In addition to a blood pressure lowering effect, it has a cardioprotective action in patients with hypertension or angina pectoris by reducing the cardiac load through a heart rate lowering effect and by increasing the oxygen supply through a coronary vasodilating effect.			
Tanatril (Imidapril)	Launch: Dec. 1993	Category	ACE inhibitor (Treatment of hypertension)
Tanatril shows excellent blood pressure control with effective organ protection as well as minimal incidence of dry cough, a common side effect of ACE inhibitors. With the approval of an additional indication in January 2002, it became the first drug in Japan approved for diabetic nephropathy with type I diabetes mellitus.			
TETRABIK (Absorbed Diphtheria-purified Pertussis-tetanus inactivated polio	Launch: Oct. 31. 2012	Category	Prevention of Diphtheria, Pertussis, Tetanus and polio
TETRABIK is a combined vaccine that prevents acute poliomyelitis (polio), pertussis, diphtheria and tetanus. It is used at 1st term (initial 3 times) and 1st term (additional 1 time), in total 4 times, of the regular vaccination. By using TETRABIK, It is expected to avoid the very rare occurrence of paralytic symptoms similar to those in natural polio due to live-attenuated oral polio vaccine. Origin, Manufacturer and distributor: BIKEN (The Research Foundation for Microbial Diseases of Osaka University)			

News Releases

The major news releases after October, 2014 are as follows.
Please refer to the Company's website for the details. (http://www.mt-pharma.co.jp/e/release/index.php)

Date	Contents
October 30, 2014	Applications filed for REMICADE for I.V. Infusion 100, an anti-human TNFα monoclonal antibody, for additional indications for entero-Behcet's disease, neuro-Behcet's disease, and vasculo-Behcet's disease
November 6, 2014	Supporting "good blood glucose control" in Japanese patients with diabetes joint promotion with Johnson & Johnson K.K. Medical Company
November 13, 2014	Application filed for additional indication for ALS for RADICUT inj. 30mg and RADICUT BAG for I.V. Infusion 30mg
November 28, 2014	Notice regarding conclusion of the final agreement for the transfer of the Kashima Plant of Mitsubishi Tanabe Pharma Factory Ltd.
December 18, 2014	Reorganization of the U.S. Affiliates to Accelerate the U.S. Operations Expansion
January 29, 2015	-Increasing Production Capacity to Meet Growing Asian Pharmaceutical Markets -Completion of New Manufacturing FacilityTianjin Tanabe Seiyaku Co., Ltd. and P.T. Tanabe Indonesia
February 6, 2015	Completion of Construction of the New Head Office Building
February 25, 2015	Reorganization of research bases in Japan
February 25, 2015	Medicago Develops Alternative Production Process for Ebola Antibodies Contract concluded with U.S. government
April 1, 2015	Execution of License Agreement on VMAT2 Inhibitor NBI-98854